Dr. Jeetendra Ambulge
Mr. Otto Prange
Board Member, CPA.
Babatunde A. (“Tunde”) Ogunnaike is the William L. Friend Chaired professor of Chemical Engineering and Dean of the College of Engineering at the University of Delaware. He received the B.Sc. degree in Chemical Engineering from the University of Lagos, Nigeria; the M.S. degree, in Statistics and the Ph.D. degree in Chemical Engineering both from the University of Wisconsin–Madison. He was named a fellow of the American Institute of Chemical Engineers in 2009, and elected to fellowship of the Nigerian Academy of Engineering and elected to the US National Academy of Engineering both in 2012.
Dr. Babatunde Ogunnaike
Dr. Sarfaraz K. Niazi
CEO & Director of Vitane Biologics
Dr Jeetendra K. Ambulge, possesses more than 23 years of experience in Biosimilars development, Bioremediation and Technology Transfer missions. With educational background in Nanobiotechnology and Ph.D. under his belt, he has made original contributions to developing various biosimilars during his long stint at Wockhardt Ltd. His work resulted in 49 patents being filed in India and WIPO, along with couple of books for students of Biotechnology and Pharmacy. In his current role at Vitane Biologics, he figures as one of India’s prominent industrial biotechnologists of recent times.
Vitane Pharma GmbH, Pfaffenrieder Str. 7, D - 82515 Wolfratshausen, Germany - email@example.com
Dr. Achim Huber
Board Member – Vitane Pharma
Vitane Biologics Private Limited is a Vitane Group Company
Dr. Mohammed Sadiq Hussain Khalid
Vitane Pharma GmbH in Wolfratshausen
Prior to Vitane Pharma, Dr.Achim Huber has been a site Director and Head of Production/QP for Advance Pharma GmbH, Klocke Verpackungsservice GmbH and at Dragenopharm Berlin (Aenova Holdings) . He has also served as a research associate in parenteral production site of Schering AG
Ph.D., SI, FRSB, FAMPS, FACB
Sarfaraz K.Niazi is a renowned pioneer of biosimilars having taken several products through EMA and FDA; an inventor with 100+ bioprocessing patents, dozens of technology books, and a long history of advising regulatory agencies, including the FDA, Dr. Niazi was listed as "the most interesting man" by the Forbes magazine, for his contributions to making biosimilars accessible”.